SCHEMBL25368564

SCHEMBL25368564

CS(=O)(=O)Nc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(CCO)cc3)cs2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.48
▸ HPGD P15428 1/20 0.47
▸ DHX9 Q08211 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ RAB9A P51151 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ PHGDH O43175 1/20 0.40
▸ USP7 Q93009 1/20 0.40
▸ USP47 Q96K76 1/20 0.40
▸ NAMPT P43490 1/20 0.39
▸ POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543946 0.87 DHX9 (0.53) KDM4EHPGDDHX9TDP1ALDH1A1
SCHEMBL25368280 0.87 DHX9 (0.53) KDM4EHPGDDHX9TDP1ALDH1A1
SCHEMBL25368236 0.85 BCHE (0.46) KDM4EHPGDDHX9TDP1ALDH1A1
SCHEMBL25368447 0.85 HPGD (0.51) KDM4EHPGDDHX9TDP1ALDH1A1
SCHEMBL25369907 0.84 HPGD (0.56) KDM4EHPGDDHX9TDP1ALDH1A1
SCHEMBL25368034 0.83 KMT2A (0.60) HPGDDHX9ALDH1A1SMN1; SMN2RAB9A
SCHEMBL25368472 0.83 LMNA (0.48) KDM4EHPGDDHX9ALDH1A1SMN1; SMN2
SCHEMBL25369304 0.82 DHX9 (0.52) KDM4EHPGDDHX9TDP1ALDH1A1
SCHEMBL25368657 0.82 HPGD (0.51) KDM4EHPGDDHX9TDP1ALDH1A1
SCHEMBL30544037 0.82 DHX9 (0.52) KDM4EHPGDDHX9TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
EP-4479380-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 — — EP disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B KDM4E 1934/4885HPGD 852/4885DHX9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback